Markers of thyroid dysfunction in patients with MDR tuberculosis

<b>The Aim:</b> to study of thyroid state in patients with newly detected MDR tuberculosis (TB) during the 6-month treatment. <b>Materials and Methods:</b> we studied the level of thyroid stimulating hormone (TSH), free thyroxine (FT4) and triyodtironina (FT3), antibodies to thyroglobulin (Ab-TG) and antibodies to thyroid peroxidase (Ab-TPO) in sera of 26 patients. The level of all indicators initially was normal. The patients were treated with antituberculotic drugs including ethionamide/protionamide and PAS. <b>Results:</b> It was found that during the treatment pathological changes were observed in levels of TSH, FT4 and Ab-TPO. Increased level of TSH in different periods of chemotherapy was observed in 61,5% of cases. Highest TSH values were detected at 4 and 5 months of chemotherapy. The mean values of TSH from 1 month of chemotherapy and during the whole observation period was significantly higher than normal values. Reducing FT4 during treatment was observed in 14.8% of patients. The level of FT4 in all observation period was significantly reduced compared with the norm. Level of Ab-TPO began to grow with the 3rd month of chemotherapy, and also peaked at 4 and 5 months of chemotherapy. <b>Conclusion:</b> The use of ethionamide/ protionamide and PAS in patients with newly detected MDR TB was accompanied by symptoms of hypothyroidism during the entire period of observation. Most often, these changes were detected in the first two months of chemotherapy. The most pronounced pathological changes in the indicators of thyroid function were observed at 4 and 5 months of treatment.